Pirfenidone Shows Hints of Benefit for RA-Related Lung Disease

(MedPage Today) -- BARCELONA -- Rheumatoid arthritis patients with existing interstitial lung disease (ILD) had less decline in lung function when receiving the antifibrotic agent pirfenidone (Esbriet) relative to placebo in a randomized trial...
Source: MedPage Today Rheumatology - Category: Rheumatology Source Type: news